Cases and Conversations: Translating ctDNA Into Clinical Decisions in Breast Cancer

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

In this podcast, experts Neil Iyengar, MD; Kelly Elizabeth McCann, MD, PhD; and Wassim Mchayleh, MD, MBA, FACP, discuss the clinical applications and current evidence for using circulating tumor DNA (ctDNA) testing in early-stage and metastatic breast cancer.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Interpret ctDNA and molecular residual disease (MRD) data from clinical trials to inform patient-centered decision-making in early-stage and metastatic breast cancer
• Apply evidence from ctDNA-guided studies to determine when liquid biopsy testing may appropriately inform clinical decision-making in breast cancer

Acknowledgment of Educational Grant Support

This activity is supported by an educational grant from Natera, Inc.

Chair:

Neil M. Iyengar, MD​

Associate Professor, Department of Hematology and Medical Oncology​
Co-Director, Breast Medical Oncology, Department of Hematology and Medical Oncology​
Director, Cancer Survivorship Services​, Winship Cancer Institute
Emory University School of Medicine​
Atlanta, GA​

Disclosures: Consultant/Advisor: Arvinas, AstraZeneca, BD Life Sciences, Daiichi Sankyo, Genentech/Roche, Gilead, Menarini-Stemline, Novartis, Pfizer, Puma, Seagen, TerSera Therapeutics; Speaker: Cardinal Health, Curio Sciences, DAVA Oncology, IntrinsiQ Health; Editorial Position: npj Breast Cancer, Oncology®; Equity/ Ownership: Complement Theory, Bettering Company; Research Support (to institution): American Cancer Society, Breast Cancer Research Foundation, Conquer Cancer Foundation, Kat’s Ribbon of Hope, National Cancer Institute/National Institutes of Health; Contracted Research: Novartis, SynDevRx

Faculty:

Kelly Elizabeth McCann, MD, PhD

Assistant Clinical Professor
David Geffen School of Medicine
Jonsson Comprehensive Cancer Center
UCLA Hematology and Oncology
Los Angeles, CA

Disclosures: Advisor, Consultant, Fee-for-Service Recipient: Arvinas, AstraZeneca, BioNTech, Biotheranostics, Biovica, Daiichi Sankyo, Eli Lilly, Halda Therapeutics OpCo, Novartis, Pfizer, Puma Biotech, Sermonix, Stemline, Summit Therapeutics, TerSera; Speakers Bureau: Eli Lilly; Grant/Research Funding: Ambrx, AstraZeneca, BriaCell, Duality Biologics, Eli Lilly, G1 Therapeutics, Gilead, H3 Biomedicine, Immunomedics, MacroGenics, Marengo Therapeutics, Merck, Novartis, Olema, Pfizer, Puma Biotech, Roche/Genentech, Sanofi, Stemline, Zymeworks

Wassim Mchayleh, MD, MBA, FACP

Medical Director, Breast Oncology
AdventHealth Cancer Institute
Orlando, FL

Disclosures: Advisor, Consultant, Fee-for-Service Recipient: AstraZeneca, DSI, Eli Lilly and Company, Gilead Sciences, Merck, SAGA, Stemline; Speakers Bureau: AstraZeneca, DSI, Eli Lilly and Company, Gilead Sciences, Merck, Stemline

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

The staff of Physicians’ Education Resource^®, LLC, have no relevant financial relationships with ineligible companies.

This podcast, including the narration, was developed by PER^® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.

To learn more about this topic, including how experts apply emerging data from clinical trials to real-world scenarios, go to https://www.gotoper.com/courses/cases-and-conversations-translating-ctdna-into-clinical-decisions-in-breast-cancer-62sc.

Release Date

April 30, 2026

Expiration Date

April 30, 2027

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.